



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com


www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Ulixertinib hydrochloride

Chemical Properties

CAS No. :	1956366-10-1
Formula:	C ₂₁ H ₂₃ Cl ₃ N ₄ O ₂
Molecular Weight:	469.79
Appearance:	no data available
Storage:	keep away from moisture
	Powder: -20°C for 3 years In solvent: -80°C for 1 year



Biological Description

Description	Ulixertinib hydrochloride (Ulixertinib HCl) is an orally available, selective and potent ERK1/2 inhibitor with anticancer and antitumor activity that inhibits the NB cell cycle and promotes apoptosis, and may be used in the study of solid tumors.
Targets(IC50)	ERK
In vitro	Combined treatment with Ulixertinib hydrochloride and VS-5584 for 48 hours significantly induced cell death in human pancreatic adenocarcinoma (HPAC) cells from the PDAC cell lines BxPC-3, MIAPaCa-2 and CFPAC. [1]
In vivo	Ulixertinib hydrochloride potently inhibited neuroblastoma tumor growth and prolonged the overall survival of the treated mice in two different neuroblastoma mice models. [2]

Solubility Information

Solubility	H ₂ O: 0.1 mg/mL(insoluble) DMSO: 80 mg/mL (170.29 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.1286 mL	10.6431 mL	21.2861 mL
5 mM	0.4257 mL	2.1286 mL	4.2572 mL
10 mM	0.2129 mL	1.0643 mL	2.1286 mL
50 mM	0.0426 mL	0.2129 mL	0.4257 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Ning C, et al. Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer. Oncotarget. 2017 Jul 4;8(27):44295-44311.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481